FCGR3A and neoplasm: To delve into this, in the study by D’Aloia and colleagues, it has been shown that CD16A-CAR-engineered T cells can mediate granule-independent cytotoxicity and enhance anti-tumour efficacy by combining monoclonal antibodies (mAbs) with T cell immune responses [89].